A logic-gated chimeric antigen receptor T-cell (CAR T) therapy with an armored, membrane-tethered IL-12 booster in patients with advanced solid tumors with HLA-A*02 loss of heterozygosity (LOH): EVEREST-2, a phase 1/2 study.
Journal of Clinical Oncology · 2026-05-28
Corrigendum to “Recurrent Transcriptional Responses in AML and MDS patients Treated with Decitabine” Experimental Hematology. 2022;111:50-65
Experimental Hematology · 2026-04-17
BASECAMP-1 screening study: a model for efficient enrolment in precision oncology clinical trials
BMJ Oncology · 2026-01-01
Recommendations for Defining Chimeric Antigen Receptor T-Cell (CAR T) Dose-Limiting Toxicities (DLTs) for Future Early-Phase CAR T Therapy Studies
Transplantation and Cellular Therapy · 2025-11-01 · 1 citations
585 DENALI-1: a seamless phase 1/2 study of A2B395, a logic-gated, allogeneic, Tmod CAR T therapy, in patients with EGFR-expressing solid tumors with human leukocyte antigen-A*02 loss of heterozygosity
Regular and Young Investigator Award Abstracts · 2025-11-01 · 1 citations
535 EVEREST-2: a phase 1/2 study of A2B694, a logic-gated Tmod CAR T therapy to treat solid tumors expressing mesothelin (MSLN) with HLA-A*02 loss of heterozygosity: initial safety and efficacy results
Regular and Young Investigator Award Abstracts · 2025-11-01 · 2 citations
Logic-gated, allogeneic Tmod chimeric antigen receptor T-cell (CAR T) therapy targeting epidermal growth factor receptor (EGFR) in advanced solid tumors with human leukocyte antigen (HLA) loss of heterozygosity (LOH): DENALI-1 trial.
Journal of Clinical Oncology · 2025-05-28 · 4 citations
EVEREST-2: Initial data of the logic-gated Tmod chimeric antigen receptor T-cell (CAR T) therapy A2B694 for patients with solid tumors associated with mesothelin (MSLN) expression and with human leukocyte antigen (HLA) loss of heterozygosity (LOH).
Journal of Clinical Oncology · 2025-05-28 · 6 citations
Abstract CT186: EVEREST-2: A seamless phase 1/2 study of A2B694, a logic-gated Tmod CAR T-cell therapy, in patients with mesothelin-expressing solid tumors with human leukocyte antigen-A*02 loss of heterozygosity
Cancer Research · 2025-04-25
Recommendations for Defining Chimeric Antigen Receptor T-Cell (CAR T) Dose-Limiting Toxicities (DLTs) for Future Early-Stage CAR T Therapy Studies
Transplantation and Cellular Therapy · 2025-02-01
EVEREST-2: A seamless phase 1/2 study of A2B694, a logic-gated Tmod chimeric antigen receptor T-cell (CAR T) therapy, in patients with pancreatic cancer (PANC) or other mesothelin (MSLN)-expressing solid tumors and human leukocyte antigen (HLA)–A*02 loss of heterozygosity (LOH).
Journal of Clinical Oncology · 2025-01-27 · 1 citations
Correlation of mesothelin (MSLN) expression measured by RNA sequencing (RNASeq) and immunohistochemistry (IHC) in MSLN-expressing tumors.
Journal of Clinical Oncology · 2025-01-27 · 1 citations
627 EVEREST-2: a seamless phase 1/2 study of A2B694, a logic-gated Tmod CAR T-cell therapy, in patients with mesothelin-expressing solid tumors with human leukocyte antigen-A*02 loss of heterozygosity
Regular and Young Investigator Award Abstracts · 2024-11-01
Monitoring clonal burden as an alternative to blast count for myelodysplastic neoplasm treatment response
Leukemia · 2024-10-04
Detecting HLA loss of heterozygosity within a standard diagnostic sequencing workflow for prognostic and therapeutic opportunities
npj Precision Oncology · 2024-08-05 · 14 citations